Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 8 | Cell Communication and Signaling

Fig. 8

From: GG-NER’s role in androgen receptor signaling inhibitor response for advanced prostate cancer

Fig. 8

Experimental validation of ACTL6A’s role in enzalutamide sensitivity. A&B. Western blot validation of ACTL6A knockdown efficiency by siRNA. C&D. CCK-8 assay detecting changes in sensitivity to enzalutamide (0µM, 2.5µM, 5µM, 12.5µM, 25µM, 50µM; and each treatment gradient was set with five replicates) after ACTL6A knockdown (duration of siRNA transfection for 48 h). E&F. Colony formation assay assessing changes in sensitivity to enzalutamide post-ACTL6A knockdown (siRNA transfection was performed every 96 h). G. Western blot validation of ACTL6A knockdown efficiency by shRNA. H. Overall image of subcutaneous xenografts in different treatment groups. I. Tumor volume changes across different groups. J. Tumor weight across different groups

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X